[HTML][HTML] Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases

X Jin, GY Yang - Progress in Lipid Research, 2023 - Elsevier
Glycosphingolipids (GSLs) are major amphiphilic glycolipids present on the surface of living
cell membranes. They have important biological functions, including maintaining plasma …

Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells

Z Nian, X Zheng, Y Dou, X Du, L Zhou, B Fu, R Sun… - Clinical Cancer …, 2021 - AACR
Purpose: Ongoing clinical trials show limited efficacy for Chimeric antigen receptor (CAR) T
treatment for acute myeloid leukemia (AML). The aim of this study was to identify potential …

CAR T cell therapy for pediatric brain tumors

JD Patterson, JC Henson, RO Breese… - Frontiers in …, 2020 - frontiersin.org
Chimeric Antigen Receptor (CAR) T cell therapy has recently begun to be used for solid
tumors such as glioblastoma multiforme. Many children with pediatric malignant brain …

Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods

LN Gonzalez Castro, I Liu, M Filbin - Neuro-oncology, 2023 - academic.oup.com
Genomic and transcriptional heterogeneity is prevalent among the most common and
aggressive primary brain tumors in children and adults. Over the past 20 years, advances in …

Immune microenvironment and immunotherapies for diffuse intrinsic pontine glioma

Y Chen, C Zhao, S Li, J Wang, H Zhang - Cancers, 2023 - mdpi.com
Simple Summary Diffuse intrinsic pontine glioma (DIPG) is a malignant primary glial tumor
that occurs in all age groups but predominates in children and is estimated to account for …

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

P Zuo, Y Li, C He, T Wang, X Zheng, H Liu… - Frontiers in …, 2023 - frontiersin.org
Background Diffuse intrinsic pontine gliomas (DIPGs) are rare and fatal pediatric brainstem
gliomas with no cure. Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells …

Updated clinical perspectives and challenges of chimeric antigen receptor-T cell therapy in colorectal cancer and invasive breast cancer

Y Cao, SK Efetov, M He, Y Fu, NM Beeraka… - Archivum Immunologiae …, 2023 - Springer
In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has
increased worldwide and caused a higher mortality rate due to the lack of selective anti …

Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy

P Chuntova, KM Downey, B Hegde… - Frontiers in …, 2019 - frontiersin.org
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo-and
radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T …

[HTML][HTML] Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas

A Noon, S Galban - Neoplasia, 2023 - Elsevier
Diffuse midline glioma (DMG) is the leading cause of brain tumor-related deaths in children.
DMG typically presents with variable neurologic symptoms between ages 3 and 10 …

Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cells

S Meril, O Harush, Y Reboh, T Matikhina… - Molecular …, 2020 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cells treatment demonstrate the increasing and powerful
potential of immunotherapeutic strategies, as seen mainly for hematological malignancies …